ANAB · Anaptysbio, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.56M | - | $76.32M | $22.26M | $27.77M | - | $30.02M | $10.97M | $7.18M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.99M | - | $31.41M | $37.82M | $41.18M | - | $42.21M | $42.00M | $37.04M | - |
| SG&A | $26.20M | - | $10.21M | $10.61M | $14.13M | - | $10.56M | $9.29M | $12.34M | - |
| Total Operating Expenses | $60.19M | - | $41.62M | $48.43M | $55.31M | - | $52.77M | $51.29M | $49.38M | - |
| D&A | $130.0K | - | - | - | $146.0K | - | - | - | $163.0K | - |
| Operating Income | ($34.64M) | - | $34.70M | ($26.17M) | ($27.54M) | - | ($22.76M) | ($40.32M) | ($42.20M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $40.0K | - | $0 | $39.0K | $0 | - | $0 | $9.0K | - | - |
| Net Income | ($52.88M) | - | $15.11M | ($38.63M) | ($39.33M) | - | ($32.85M) | ($46.66M) | ($43.94M) | - |
| EPS - Basic | ($1.84) | - | $0.36 | ($0.89) | ($0.85) | - | ($0.76) | ($1.14) | ($1.09) | - |
| EPS - Diluted | ($1.84) | - | $0.35 | ($0.89) | ($0.85) | - | ($0.76) | ($1.14) | ($1.09) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $248.47M | $238.20M | $109.83M | $44.30M | $98.64M | $123.08M | $191.58M | $71.82M | $53.70M | $35.97M |
| Accounts Receivable | $25.75M | $33.85M | $75.69M | $21.42M | $17.88M | $40.77M | $12.20M | $9.01M | $7.09M | $6.85M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.52M | $3.87M | $2.89M | $3.33M | $6.12M | $4.00M | $3.59M | $4.89M | $4.58M | $4.70M |
| Current Assets | $316.11M | $350.25M | $330.65M | $291.91M | $363.11M | $431.88M | $448.68M | $367.35M | $372.42M | $406.83M |
| Total Assets | $329.68M | $364.39M | $353.10M | $335.25M | $422.05M | $483.83M | $493.42M | $427.38M | $405.83M | $452.39M |
| Current Liabilities | $41.70M | $38.63M | $38.10M | $35.53M | $44.04M | $45.43M | $43.88M | $40.42M | $32.30M | $37.44M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $12.75M | $37.21M | ($29.42M) | ($44.73M) | $34.02M | $70.87M | $84.37M | $9.88M | $47.78M | $88.10M |
| Retained Earnings | ($825.44M) | ($772.56M) | ($822.17M) | ($837.29M) | ($798.66M) | ($759.33M) | ($737.54M) | ($704.69M) | ($658.03M) | ($614.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($25.92M) | - | - | - | ($10.70M) | - | - | - | ($37.25M) | - |
| Investing Cash Flow | $34.98M | - | - | - | $14.85M | - | - | - | $68.62M | - |
| Financing Cash Flow | $1.21M | - | - | - | ($28.59M) | - | - | - | ($13.63M) | - |
| CapEx | $17.0K | - | - | - | $35.0K | - | - | - | $27.0K | - |
| Free Cash Flow | ($25.94M) | - | - | - | ($10.73M) | - | - | - | ($37.28M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -135.5% | - | 45.5% | -117.5% | -99.2% | - | -75.8% | -367.5% | -587.8% | - |
| EBITDA margin | -135.0% | - | - | - | -98.6% | - | - | - | -585.6% | - |
| Net margin | -206.9% | - | 19.8% | -173.5% | -141.6% | - | -109.4% | -425.3% | -612.0% | - |
| Free cash flow margin | -101.5% | - | - | - | -38.7% | - | - | - | -519.3% | - |
| FCF / Net income | 0.49 | - | - | - | 0.27 | - | - | - | 0.85 | - |
| R&D / Revenue | 133.0% | - | 41.2% | 169.9% | 148.3% | - | 140.6% | 382.8% | 516.0% | - |
| SG&A / Revenue | 102.5% | - | 13.4% | 47.7% | 50.9% | - | 35.2% | 84.7% | 171.9% | - |
| Effective tax rate | - | - | 0.0% | - | - | - | - | - | - | - |
| Return on assets | -16.0% | - | 4.3% | -11.5% | -9.3% | - | -6.7% | -10.9% | -10.8% | - |
| Return on equity | -414.9% | - | -51.4% | 86.4% | -115.6% | - | -38.9% | -472.3% | -92.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.58 | 9.07 | 8.68 | 8.22 | 8.25 | 9.51 | 10.23 | 9.09 | 11.53 | 10.87 |
| Quick ratio | 7.58 | 9.07 | 8.68 | 8.22 | 8.25 | 9.51 | 10.23 | 9.09 | 11.53 | 10.87 |
| Cash ratio | 5.96 | 6.17 | 2.88 | 1.25 | 2.24 | 2.71 | 4.37 | 1.78 | 1.66 | 0.96 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 25.86 | 9.79 | -12.00 | -7.49 | 12.41 | 6.83 | 5.85 | 43.26 | 8.49 | 5.13 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.08 | - | 0.22 | 0.07 | 0.07 | - | 0.06 | 0.03 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 368d | - | 362d | 351d | 235d | - | 148d | 300d | 360d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 58.9x | - | - | - | - | - | - | - |
| P / B | 83.2x | - | - | - | 11.2x | - | 7.6x | 46.3x | 8.4x | - |
| P / S | 41.5x | - | 7.8x | 19.2x | 13.7x | - | 21.5x | 41.7x | 56.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -8.0% | - | 154.3% | 102.9% | 286.8% | - | 804.7% | 217.1% | 422.5% | - |
| Revenue CAGR (3y) | 165.0% | - | 289.4% | 163.6% | 205.9% | - | 12.8% | -28.5% | -13.9% | - |
| Revenue CAGR (5y) | 17.8% | - | - | - | 13.1% | - | - | 17.0% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -25.8% | - | - | 35.1% | 34.7% | - | 39.7% | -0.4% | 5.0% | - |
| Net income growth (YoY) | -34.5% | - | - | 17.2% | 10.5% | - | 11.9% | -17.1% | 0.7% | - |
| EPS growth (YoY) | -115.6% | - | - | 21.6% | 22.0% | - | 46.1% | 24.0% | 30.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -141.6% | - | - | - | 71.2% | - | - | - | -50.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.5% | -47.5% | - | - | -28.8% | -19.6% | -29.9% | -93.3% | -75.0% | -66.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$234.60M totalRoyalty Management Company$234.60M · 100.0%
Product / service
$134.70M totalAnaptys Bio Generated Anti PD1 Jemperli Dostarlimab$125.00M · 92.8%
License$9.50M · 7.1%
Transaction Service$200.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ANAPTYSBIO against the 5 most active filers in the same SIC group.